HANCOCK WHITNEY CORP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.

Quarter-by-quarter ownership
HANCOCK WHITNEY CORP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$224,503
+2.5%
5,877
-3.4%
0.01%0.0%
Q2 2023$219,000
-32.0%
6,084
-27.8%
0.01%
-30.8%
Q1 2023$322,000
-40.9%
8,429
-12.0%
0.01%
-38.1%
Q4 2022$545,000
+43.8%
9,577
-0.2%
0.02%
+31.2%
Q3 2022$379,000
-6.4%
9,597
+4.2%
0.02%0.0%
Q2 2022$405,000
+2.8%
9,211
-6.8%
0.02%
+23.1%
Q1 2022$394,000
+0.5%
9,881
+1.3%
0.01%
+8.3%
Q4 2021$392,000
-1.8%
9,753
-0.7%
0.01%
-14.3%
Q3 2021$399,000
-13.3%
9,820
-3.0%
0.01%
-6.7%
Q2 2021$460,000
-55.3%
10,120
-59.0%
0.02%
-57.1%
Q1 2021$1,030,000
-3.9%
24,698
-1.6%
0.04%
-2.8%
Q4 2020$1,072,000
+62.7%
25,092
+0.1%
0.04%
+50.0%
Q3 2020$659,000
-2.1%
25,060
-0.2%
0.02%
-7.7%
Q2 2020$673,000
+9.1%
25,098
-26.8%
0.03%
+8.3%
Q1 2020$617,000
+41.2%
34,274
+39.2%
0.02%
+71.4%
Q4 2019$437,000
-21.1%
24,627
-31.1%
0.01%
-22.2%
Q3 2019$554,000
-29.1%
35,718
-21.4%
0.02%
-28.0%
Q2 2019$781,000
+20.5%
45,439
+12.9%
0.02%
+19.0%
Q1 2019$648,000
+40.0%
40,260
+27.3%
0.02%
+31.2%
Q4 2018$463,000
-44.7%
31,630
-31.4%
0.02%
-33.3%
Q3 2018$838,000
+18.0%
46,115
+9.6%
0.02%
-27.3%
Q2 2018$710,00042,0630.03%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders